Reporting from Chicago - A new Migraine abortive in trials.
@trobert Health Guide
Reporting from Chicago at the American Headache Society's 49th Annual Scientific Meeting...
For a couple of years now, we've been watching, with interest, the goings on in the development of a potential new class of Migraine abortive medications, CGRP receptor antagonists. The development had stalled for a while because of issues with patient-friendly ways to administer the medications.
Now, Merck has released results from their Phase II trials of MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) antagonist. I spoke with Dr. Tony Ho, senior director of Clinical Neuroscience for Merck Research Laboratories yesterday. Here's my report on our conversation and the status of the potential new Migraine abortive.
Read New Migraine Abortive Shows Promise without Vasoconstriction.
Published On: June 07, 2007